Literature DB >> 16773191

Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.

Takumi Sakuma1, Katsuhiro Uzawa, Takeshi Onda, Masashi Shiiba, Hidetaka Yokoe, Takahiko Shibahara, Hideki Tanzawa.   

Abstract

The structure and function of chromatin can be altered by modifications to histone. Histone acetylation is a reversible process governed by histone acetyltransferases and histone deacetylases (HDACs). HDAC6 is a subtype of the HDAC family that deacetylates alpha-tubulin and increases cell motility. We investigated the expression levels of HDAC6 mRNA and protein expression in oral squamous cell carcinoma (OSCC)-derived cell lines and human primary OSCCs to elucidate the potential involvement of HDAC6 in OSCC. Using quantitative real-time reverse transcription polymerase chain reaction and Western blots on nine OSCC-derived cell lines and normal oral keratinocytes (NOKs), HDAC6 mRNA and protein expression were commonly up-regulated in all cell lines compared with the NOKs. Immunofluorescence analysis detected HDAC6 protein in the cytoplasm of OSCC cell lines. Similar to OSCC cell lines, high frequencies of HDAC6 up-regulation were evident in both mRNA (74%) and protein (51%) levels of primary tumors. Among the clinical variables analyzed, the clinical tumor stage was found to be associated with the HDAC6 expression states. The analysis indicated a significant difference in the HDAC6 expression level between the early stage (stage I and II) and advanced-stage (stage III and IV) tumors (P=0.014). These results suggest that HDAC6 expression may be correlated with tumor aggressiveness and offer clues to the planning of new treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773191

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  75 in total

Review 1.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

2.  HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report.

Authors:  Gonçalo Esteves; Joana Ferreira; Rita Afonso; Carmo Martins; Carlos Zagalo; Ana Félix
Journal:  Head Neck Pathol       Date:  2020-01-27

3.  Expression status of Zic family member 2 as a prognostic marker for oral squamous cell carcinoma.

Authors:  Kentaro Sakuma; Atsushi Kasamatsu; Masanobu Yamatoji; Yukio Yamano; Kazuaki Fushimi; Manabu Iyoda; Kenji Ogoshi; Keiji Shinozuka; Katsunori Ogawara; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-27       Impact factor: 4.553

4.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.

Authors:  Theodoros N Teknos; J Grecula; A Agrawal; M O Old; E Ozer; R Carrau; S Kang; J Rocco; D Blakaj; V Diavolitsis; B Kumar; P Kumar; Q Pan; M Palettas; L Wei; R Baiocchi; P Savvides
Journal:  Invest New Drugs       Date:  2018-12-19       Impact factor: 3.850

Review 5.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.

Authors:  S Spiegel; S Milstien; S Grant
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

Review 6.  Epigenetic mechanisms in oral carcinogenesis.

Authors:  Jacqueline A Gasche; Ajay Goel
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

7.  Comparative genomic study of gastric epithelial cells co-cultured with Helicobacter pylori.

Authors:  Fen Wang; Li-Dan Luo; Jian-Hua Pan; Li-Hua Huang; Hong-Wei Lv; Qin Guo; Can-Xia Xu; Shou-Rong Shen
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

8.  HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.

Authors:  Linlin Zhang; Ningning Liu; Songbo Xie; Xianfei He; Jun Zhou; Min Liu; Dengwen Li
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

9.  Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

Authors:  Annunziata Gloghini; Daniela Buglio; Noor M Khaskhely; Georgios Georgakis; Robert Z Orlowski; Sattva S Neelapu; Antonino Carbone; Anas Younes
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

10.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Authors:  L Marquard; L M Gjerdrum; Ib J Christensen; P B Jensen; M Sehested; E Ralfkiaer
Journal:  Histopathology       Date:  2008-09       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.